Ubs Group Ag Soleno Therapeutics Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$0.14 - $0.23 $7,657 - $12,579
54,695 New
54,695 $10,000
Q1 2022

May 16, 2022
SELL
$0.22 - $0.47 $6,646 - $14,199
-30,211 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$0.41 - $0.91 $5,701 - $12,653
13,905 Added 85.28%
30,211 $12,000
Q3 2021

Nov 15, 2021
BUY
$0.8 - $1.12 $12,275 - $17,185
15,344 Added 1595.01%
16,306 $15,000
Q2 2021

Aug 13, 2021
SELL
$0.97 - $1.32 $34,933 - $47,538
-36,014 Reduced 97.4%
962 $1,000
Q1 2021

May 12, 2021
BUY
$1.24 - $3.3 $33,444 - $89,004
26,971 Added 269.58%
36,976 $47,000
Q4 2020

Feb 11, 2021
SELL
$1.61 - $2.23 $20,271 - $28,077
-12,591 Reduced 55.72%
10,005 $19,000
Q3 2020

Nov 12, 2020
BUY
$1.71 - $2.51 $6,759 - $9,922
3,953 Added 21.2%
22,596 $57,000
Q2 2020

Jul 31, 2020
BUY
$1.77 - $4.23 $23,640 - $56,495
13,356 Added 252.62%
18,643 $41,000
Q1 2020

May 01, 2020
BUY
$1.64 - $3.85 $5,741 - $13,478
3,501 Added 196.02%
5,287 $13,000
Q4 2019

Feb 14, 2020
SELL
$1.35 - $2.95 $3,981 - $8,699
-2,949 Reduced 62.28%
1,786 $5,000
Q3 2019

Nov 14, 2019
BUY
$1.5 - $2.99 $486 - $968
324 Added 7.35%
4,735 $7,000
Q2 2019

Aug 14, 2019
SELL
$1.93 - $2.95 $2,659 - $4,065
-1,378 Reduced 23.8%
4,411 $12,000
Q1 2019

May 14, 2019
BUY
$1.35 - $2.68 $5,062 - $10,050
3,750 Added 183.91%
5,789 $12,000
Q4 2018

Feb 14, 2019
BUY
$1.55 - $2.3 $3,160 - $4,689
2,039 New
2,039 $3,000
Q3 2018

Nov 14, 2018
SELL
$1.95 - $3.07 $7,751 - $12,203
-3,975 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$1.56 - $3.1 $2,496 - $4,960
1,600 Added 67.37%
3,975 $9,000
Q1 2018

May 15, 2018
BUY
$1.56 - $2.12 $3,705 - $5,035
2,375 New
2,375 $4,000

About SOLENO THERAPEUTICS INC

SLNO Quotes by TradingView
  • Ticker SLNO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,101,250
  • Market Cap $413M
  • Description
  • Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing P...
More about SLNO
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email